Clarivate for Life Sciences & Healthcare

The Future of Breast Cancer Therapies is Here The breast cancer treatment landscape is evolving rapidly, making it essential to stay ahead of the latest trends. The Clarivate Breast Cancer Disease Landscape & Forecast report delivers actionable insights to help you navigate the future of breast cancer therapies with confidence. Explore how CDK4/6 inhibitors are driving sales growth in HR-positive/HER2-negative breast cancer, how biomarker-driven therapies like Piqray and Orserdu are addressing endocrine resistance, and the rise of Enhertu in HER2-positive disease. Plus, gain insights into how immune checkpoint inhibitors and TROP2-targeted agents are shaping earlier treatment lines for triple-negative breast cancer. Backed by expert interviews, advanced epidemiology, and real-time drug pipeline data from Cortellis, this comprehensive report provides the strategic intelligence needed to navigate key markets across the U.S., EU5, and Japan. Why This Report Matters: ? Gain a deep understanding of market trends and key drug approvals ? Identify the therapies driving market shifts and the leading agents in the pipeline ? Access a sample deck and brochure to explore insights before making your decision Stay ahead in the evolving breast cancer landscape. Request more information today and take the next step toward securing your competitive advantage. ?? Download the brochure and access the sample deck here: https://lnkd.in/eF3RcXfJ This is your chance to stay ahead of the competition with valuable, data-driven insights. Get started now! #HealthcareInnovation #BreastCancer #MarketInsights #PharmaceuticalIndustry #LeadGeneration #CancerTreatment #Report

Thank You for Connecting with Us at the Society of Toxicology (SOT) 64th Annual Meeting & ToxExpo Thank you to everyone who visited Clarivate at the Society of Toxicology (SOT) 64th Annual Meeting & ToxExpo in Orlando. It was a great opportunity to engage with professionals from the toxicology, research, and pharmaceutical sectors. A special thank you to our expert speakers: ?? Kinsi Oberoi, Senior Solutions Consultant at Clarivate ?? Brian Mautz, Senior Principal Scientist at Janssen R&D ?? Evan H. Baugh, PhD, Principal Scientist at Janssen R&D Their presentation on Target Selection and Safety Assessment (TSAs) provided valuable insights into how TSAs support Go/No-Go decisions throughout the drug development process. We were also pleased to showcase our OFF-X Translational Safety Intelligence platform, trusted by the FDA, at Booth #1401. Our team—including Christine DeMeo, Ramon Flores Pons, Matthew Wampole, James Polinski, and Max Mills—demonstrated how our AI-powered platform helps identify and address safety concerns early in the drug development lifecycle. If we missed you at the event, we invite you to stay connected. Reach out to our team to learn more about OFF-X Translational Safety Intelligence—a unique solution designed to anticipate risks and drive new competitive value in drug development: https://lnkd.in/eSbBAbvy #2025SOT #ToxExpo #Toxicology #DrugDevelopment #Clarivate #Innovation

Unlock the Future of Alzheimer’s Treatment! The DRG Disease Landscape & Forecast (G7) report provides in-depth insights into the latest trends and cutting-edge developments in Alzheimer’s disease treatment. Key insights include: ?? Beta-Amyloid MAbs are revolutionizing treatment pathways. ?? Leqembi (Eisai/Biogen) & Kisunla (Eli Lilly) now compete in the early AD space – U.S. and Japan approvals are a game-changer! ?? Next-gen DMTs like Eli Lilly’s remternetug and Novo Nordisk’s semaglutide are on the horizon, offering hope for new treatment options. ?? Neuropsychiatric symptom management is making strides, with new FDA-approved treatments like Rexulti (Lundbeck/Otsuka) leading the way. Book a demo, download the sample deck and brochure to explore these key trends and dive deeper into the competitive dynamics of the Alzheimer’s Disease market. ?? Request for more info: https://lnkd.in/ddKN_um4 #AlzheimersDisease #Pharma #Research #Healthcare #MarketForecast

What makes Fitusiran a 2025 blockbuster drug? Fitusiran, a Phase 3 siRNA therapeutic developed by Sanofi and Alnylam? Pharmaceuticals, is set to transform the treatment landscape for hemophilia A and B, regardless of inhibitor status. By targeting and inhibiting antithrombin production in the liver, Fitusiran promotes thrombin generation, aiding in clotting says Sayani Datta, Manager, Healthcare Research & Data Analytics, Clarivate. With its convenient subcutaneous dosing once a month (or every other month), it reduces treatment burden and enhances patient compliance. We forecast Fitusiran will capture over $1B in major markets by 2033, with the most significant impact in the hemophilia B market. ?? What’s inside the 2025 Drugs to Watch report? Gain actionable insights into pivotal trends, including the growing demand for obesity treatments, the transformative promise of gene editing, and the regulatory advancements accelerating innovation. The report also delves into the chronic disease market in Mainland China, offering a global perspective on evolving healthcare dynamics. Download the full report here: https://lnkd.in/eNiVUti6 #Hemophilia #RNAtherapeutics #DrugDiscovery #DrugsToWatch

Clarivate will be at German Biotech Days 2025, hosted by BIO Deutschland e. V. in Heidelberg on April 9-10. As a leader in life sciences and healthcare, we empower innovators with AI-enabled intelligence platforms, connecting data and expertise to drive faster, safer, and more effective treatments. We invite healthcare professionals, biotech, pharma, and medtech companies to meet with us and discover how our insights and solutions can help accelerate your journey from idea to impact. ?? Let’s shape the future of biotech together. See you in Heidelberg! Book a meeting with Dr. Dr. Claudia Sellke, Senior Account Manager, Clarivate: https://lnkd.in/e7FqceYH #Biotech #Innovation #Healthcare #Clarivate

It was a dynamic session at the IV International IFAS LATAM Seminar, organized by ABIQUIFI! Clarivate had the opportunity to host the exclusive session, "Drugs to Watch 2025: What Are the Upcoming Game-Changers in the Industry?" The discussion offered a deep dive into pharmaceutical innovation, featuring insights from our Drugs to Watch 2025 report. Clarivate experts Antero Macedo, Leticia Ferreira Terra, Cristián Madoery, and J?rg H. Limberg shared valuable perspectives on the most promising therapies set to reshape the global healthcare landscape. The future of life-changing treatments is on the horizon, and it was a privilege to engage with industry leaders to explore the advancements driving it forward. Meet the Clarivate experts by booking a meeting here: https://lnkd.in/e3Ab9N66?? #PharmaceuticalInnovation #API #LATAM #IndustryLeaders #Healthcare

Unlock the Future of Market Access at Asembia’s AXS25 Summit! As market access strategies become increasingly complex, having the right tools to navigate reimbursement dynamics is more crucial than ever. How do you access and ensure the accuracy of medical policy and formulary data? How do you ensure that you have the most comprehensive payer data available? Join - Abeezer Tapia, Joe Bivins, Kyle Burleson, Kathy Bellitti, Noor Sheikh, Swaroop Satya, Joe deSimone, Gita Mishkin, Tania Leighton - at Asembia, from April 27 - May 1 at Las Vegas, to learn more about Clarivate Fingertip, the leading solution that transforms market access strategies. Fingertip offers unrivaled access to real-time formulary and medical policy data, providing your commercial teams with the insights they need for effective decision-making. With over 15 years of coverage and policy data across 35,000 drugs, Fingertip delivers precise market sizing and analysis. Track and analyze payer dynamics over time, compare data across brands and understand market trends and shifts in strategy. Book a meeting with the Clarivate team to learn more: https://lnkd.in/eiuTSp6K Learn more about Asembia’s AXS25 Summit: https://lnkd.in/eCn9yS38 #MarketAccess #Asembia2025 #HealthcareInnovation #MarketIntelligence #Clarivate

Live from the IV International IFA LATAM Seminar! Clarivate is proud to sponsor the IV International IFA LATAM Seminar, organized by ABIQUIFI, happening today at the JW Marriott Hotel in S?o Paulo. Join us to connect with industry leaders and explore the latest trends and innovations in the Active Pharmaceutical Ingredients (API) sector. By supporting this initiative, Clarivate reaffirms its commitment to advancing the sector and facilitating knowledge exchange for continuous growth. Register now: https://lnkd.in/en-3EBe7 Meet the Clarivate experts - Antero Macedo, Leticia Ferreira Terra, Cristián Madoery, and J?rg H. Limberg - by booking a meeting here: https://lnkd.in/e3Ab9N66 #PharmaceuticalInnovation #API #LATAM #IndustryLeaders #Healthcare?

Unlock Strategic Insights with Four Market Access Reports on Breakthrough Therapies Stay ahead in the evolving healthcare landscape with four in-depth market access reports analyzing the latest game-changing therapies. These reports offer critical insights into market size and growth potential, competitive dynamics, and pricing strategies—equipping you with the knowledge to navigate an increasingly complex market. Featured Reports ?? Casgevy? & Lyfgenia? The first FDA-approved cell-based gene therapies for sickle cell disease. This report examines market share growth, cost and coverage challenges, and physician perceptions. ?? AREXVY & ABRYSVO? The first FDA-approved RSV vaccines for high-risk populations. Gain insights into competitive positioning, market barriers, and patient perspectives. ?? Eylea? HD A high-dose version of aflibercept, designed to maintain market leadership amid biosimilar competition. Explore the disease landscape, pricing strategies, and stakeholder perspectives. ?? TARPEYO?/Kinpeygo? The first treatments for immunoglobulin A nephropathy. This report delves into pricing dynamics, competitive positioning, and safety considerations. Gain the competitive edge—explore the full reports today. https://lnkd.in/emFKnDzz #MarketAccess #Healthcare #TherapeuticAdvancements

Clarivate at the IV International IFAS LATAM Seminar Join Antero Macedo, Leticia Ferreira Terra, Cristián Madoery, and J?rg H. Limberg at the IV International IFAS LATAM Seminar, organized by ABIQUIFI on March 24-25. We are also excited to host an exclusive session: ?? March 25 – Drugs to Watch 2025: What Are the Upcoming Game-Changers in the Industry? This session will provide a deep dive into pharmaceutical innovation, featuring insights from the Drugs to Watch 2025 report—highlighting the most promising therapies set to shape the global market. Don’t miss this opportunity to engage with industry experts and explore the future of life-changing treatments. Stay tuned for updates! Book a meeting with the Clarivate team here: https://lnkd.in/eZke4N_n #PharmaceuticalInnovation #API #LATAM #IndustryLeaders #Healthcare